Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 6,509,038

« Back to Dashboard

Claims for Patent: 6,509,038

Title: Antifungal compositions with improved bioavailability
Abstract:The present invention is concerned with novel pharmaceutical compositions of itraconazole which can be administered to a mammal suffering from a fungal infection, whereby a single such dosage form can be administered once daily, and in addition at any time of the day independently of the food taken in by said mammal. These novel compositions comprise particles obtainable by melt-extruding a mixture comprising itraconazole and an appropriate water-soluble polymer and subsequently milling said melt-extruded mixture.
Inventor(s): Baert; Lieven Elvire Colette (Bruges, BE), Verreck; Geert (Malle, BE), Thone; Dany (Beerse, BE)
Assignee: Janssen Pharmaceutica N.V. (Beerse, BE)
Application Number:09/194,480
Patent Claims: 1. A pharmaceutical dosage form comprising a therapeutically effective amount of particles consisting of a solid dispersion comprising (a) itraconazole, or one of its stereoisomers, or a mixture of two or three or four of its stereoisomers, and (b) one or more pharmaceutically acceptable water-soluble polymers; wherein the particle has a size of less than 600 .mu.m; the solid dispersion is in the form of a solid solution comprising (a) and (b), or in the form of a dispersion wherein amorphous or microcrystalline (a) or amorphous or microcrystalline (b) is dispersed in a solid solution comprising (a) and (b) and the water-soluble polymer is a polymer that has an apparent viscosity of 1 to 100 mPa.s when dissolved in a 2% aqueous solution at 20.degree. C. solution, and wherein the dosage form further comprises by weight based on the total weight of the dosage form: 21.65% itraconazole 32.48% HPMC 2910 5 mPa.s 30.57% spray-dried lactose monohydrate:microcrystalline cellulose (75:25) mixture 8.49% crospovidone 2.79% talc 0.93% hydrogenated vegetable oil Type I 0.28% colloidal anhydrous silica 0.24% magnesium stearate, yielding 97.43% tablet core, and 1.47% HPMC 2910 5 mPa.s 0.37% propyleneglycol 0.29% talc 0.44% titanium dioxide, yielding 2.57% film-coat.

2. A method of treating a fungal infection in a mammal comprising orally administering to the mammal an effective antifungal amount of itraconazole in a pharmaceutical dosage form as claimed in claim 1, wherein said pharmaceutical dosage form can be administered once daily.

3. The method of claim 2, wherein said pharmaceutical dosage form can be administered at any time of the day independently of the food taken in by said mammal.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.